Literature DB >> 20854115

Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.

Samir K Ballas1, William F McCarthy, Nan Guo, Carlo Brugnara, Gail Kling, Robert L Bauserman, Myron A Waclawiw.   

Abstract

Red blood cells (RBC) and reticulocyte parameters were determined on peripheral blood from a subset of patients enrolled in the multicenter study of hydroxyuea (HU) in sickle cell anemia. Multiple blood samples were obtained every 2 weeks. Cellular indices were measured by flow cytometry. Generalized linear models were used to determine the relationship between the longitudinal trajectories of RBC and reticulocyte indices and HU usage. There was a significant relationship between HU usage and most of the RBC and reticulocyte indices. Hydroxyurea produced higher value trajectories than those generated by placebo usage for the hemoglobin (Hb) content of both the RBCs and reticulocytes and for the mean corpuscular volume (MCV) of reticulocytes. These changes were first detected 10 weeks after starting HU and before the increase in Hb F levels. The data suggest that subtle and early markers of response to HU reside in the hemogram.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854115     DOI: 10.3109/03630269.2010.513638

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  5 in total

1.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

Review 2.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Angela E Rankine-Mullings; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2022-09-01

Review 3.  A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Authors:  Nirmani Yasara; Anuja Premawardhena; Sachith Mettananda
Journal:  Orphanet J Rare Dis       Date:  2021-03-01       Impact factor: 4.123

Review 4.  Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective.

Authors:  Rayan Bou-Fakhredin; Lucia De Franceschi; Irene Motta; Maria Domenica Cappellini; Ali T Taher
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-16

5.  Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment.

Authors:  Fabia Neves; Osvaldo Alves Menezes Neto; Larissa Bueno Polis; Sarah Cristina Bassi; Denise Menezes Brunetta; Ana Cristina Silva-Pinto; Ivan Lucena Angulo
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.